Back to mobile site

More on VOR

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (7.5 Score)

Upcoming Events

- Earnings (8/6/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Vor Biopharma (NQ:VOR)
Delayed: 14.41 +0.32 (2.27%)
Prev. Close $14.09  
Open$14.09 
52 Wk High$ 
52 Wk Low$ 
Day High$14.83 
Day Low$14.07 
P/E N/A  
EPS$ 
Volume298,649 

Friends, Peers and Foes (?): REGMY, PRTC 688331.SS (more...)

Jun 8, 2026 04:02 PM Form 8-K Vor Biopharma Inc. For: Jun 08
Jun 8, 2026 08:31 AM Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
Jun 8, 2026 08:30 AM Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
Jun 1, 2026 05:00 PM Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 28, 2026 08:30 AM Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
May 15, 2026 04:38 PM Form SCHEDULE 13G/A Vor Biopharma Inc. Filed by: Venrock Healthcare Capital Partners III, L.P.
May 15, 2026 04:34 PM Form SCHEDULE 13G/A Vor Biopharma Inc. Filed by: Verve Capital Ltd
May 14, 2026 08:30 AM Vor Bio reports positive telitacicept trial results in kidney disease
May 14, 2026 08:30 AM Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
May 13, 2026 08:32 AM Form 10-Q Vor Biopharma Inc. For: Mar 31
View All Articles

Entities mentioned with VOR

View All Entities